Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.
暂无分享,去创建一个
[1] L. Valentino,et al. von Willebrand factor/factor VIII concentrate (Humate‐P) for management of elective surgery in adults and children with von Willebrand disease , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[2] P. Mannucci,et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand’s disease (VWD) has limited value in dosing for surgery , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[3] M. Franchini. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. , 2008, Blood transfusion = Trasfusione del sangue.
[4] P. Mannucci,et al. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery , 2007, Journal of thrombosis and haemostasis : JTH.
[5] P. Mannucci,et al. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. , 2007, Haematologica.
[6] A. Federici. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[7] Z. Berneman,et al. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII–von Willebrand factor concentrate (Haemate-P) , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[8] J. Gill,et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate‐P®) , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] J. Gill,et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] G. Lippi,et al. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. , 2003, Haematologica.
[11] D. Lillicrap,et al. Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease , 2002, Thrombosis and Haemostasis.
[12] Christine A. Lee,et al. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease , 2001, American journal of hematology.
[13] S. Lethagen. Haemostatic treatment in connection with surgery in patients with von Willebrand disease , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[14] S. Schulman,et al. Safety and Efficacy of Continuous Infusion of a Combined Factor VIII – von Willebrand Factor (vWF) Concentrate (Haemate-P™) in Patients with von Willebrand Disease , 1999, Thrombosis and Haemostasis.
[15] Chediak,et al. Pharmacokinetics, efficacy and safety of Humate‐P® in von Willebrand disease , 1998 .
[16] K. Pasi,et al. Bleeding after tonsillectomy in severe von Willebrand's disease , 1995, The Journal of Laryngology & Otology.
[17] F Rodeghiero,et al. Epidemiological investigation of the prevalence of von Willebrand's disease. , 1987, Blood.
[18] E. Ikkala,et al. [Von Willebrand's disease]. , 1967, Duodecim lääketieteellinen aikakauskirja.